Nebulized Salbutamol Facilitate Management of Hyperkalemia Postreperfusion During Liver Transplantation

• Status: Not yet recruiting
• Trial end date: 2024-01-10
• Target enrollment: 0
• Participant gender: All

Summary

The therapeutic effect of nebulized salbutamol on hyperkalemia during reperfusion in liver transplantation patients. Secondary research objectives: To observe the results of blood gas analysis, changes in urinary potassium and hemodynamic parameters, and the incidence of reperfusion syndrome in liver transplantation, and to observe the incidence of postoperative pulmonary complications during the 7-day follow-up. To explore the effect of aerosol inhalation of salbutamol on new liver reperfusion syndrome in patients with liver transplantation, and to provide a theoretical basis for clinical treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Treatments: Albuterol; Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Patients aged 20 to 70 years old;

• Cardiac function grades I to III (NYHA standard);

• Plan to undergo orthotopic liver transplantation;

• Serum potassium ion concentration greater than 4 mmol/h at the beginning of anhepatic phase;

• Those who are willing to sign the informed consent form.

Exclusion Criteria:

• Intraoperative CRRT patients;

• Those who are allergic to the test drug;

• refuse to join the trial investigator;

• Patients who are participating in other clinical trials, the researchers believe that other reasons are not suitable for clinical trials.

• Anyone with any of the above conditions cannot be selected for this trial.